Development and Validation of a 9-Gene Prognostic Signature in Patients With Multiple Myeloma

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Jan 24

PMID 30671382

Citations 11

Authors

Xiao-Ping Liu

Xiao-Hong Yin

Xiang-Yu Meng

Xin-Hui Yan

Fan Wang

Li He

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma (MM) is one of the most common types of hematological malignance, and the prognosis of MM patients remains poor. To identify and validate a genetic prognostic signature in patients with MM. Co-expression network was constructed to identify hub genes related with International Staging System (ISS) stage of MM. Functional analysis of hub genes was conducted. Univariate Cox proportional hazard regression analysis was conducted to identify genes correlated with the overall survival (OS) of MM patients. Least absolute shrinkage and selection operator (LASSO) penalized Cox proportional hazards regression model was used to minimize overfitting and construct a prognostic signature. The prognostic value of the signature was validated in the test set and an independent validation cohort. A total of 758 hub genes correlated with ISS stage of MM patients were identified, and these hub genes were mainly enriched in several GO terms and KEGG pathways involved in cell proliferation and immune response. Nine hub genes (HLA-DPB1, TOP2A, FABP5, CYP1B1, IGHM, FANCI, LYZ, HMGN5, and BEND6) with non-zero coefficients in the LASSO Cox regression model were used to build a 9-gene prognostic signature. Relapsed MM and ISS stage III MM was associated with high risk score calculated based on the signature. Patients in the 9-gene signature low risk group was significantly associated with better clinical outcome than those in the 9-gene signature high risk group in the training set, test, and validation set. We developed a 9-gene prognostic signature that might be an independent prognostic factor in patients with MM.

Citing Articles

Differential molecular characterization of human papillomavirus-associated oropharyngeal squamous cell carcinoma and its prognostic value.

Wang H, Zhang Q, Zheng Z, Xin Y, Jiang X J Cell Mol Med. 2024; 28(19):e70073.

PMID: 39397259 PMC: 11471427. DOI: 10.1111/jcmm.70073.

Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verification.

Sun C, Zhang W, Liu H, Ding Y, Guo J, Xiong S Sci Rep. 2024; 14(1):15142.

PMID: 38956267 PMC: 11219856. DOI: 10.1038/s41598-024-65937-x.

Identification of a metabolism-linked genomic signature for prognosis and immunotherapeutic efficiency in metastatic skin cutaneous melanoma.

He Z, Lyu J, Lyu L, Long X, Xu B Medicine (Baltimore). 2024; 103(23):e38347.

PMID: 38847706 PMC: 11155616. DOI: 10.1097/MD.0000000000038347.

Transcription/Replication Conflicts in Tumorigenesis and Their Potential Role as Novel Therapeutic Targets in Multiple Myeloma.

Dutrieux L, Lin Y, Lutzmann M, Rodriguez R, Cogne M, Pasero P Cancers (Basel). 2021; 13(15).

PMID: 34359660 PMC: 8345052. DOI: 10.3390/cancers13153755.

FABP5, a Novel Immune-Related mRNA Prognostic Marker and a Target of Immunotherapy for Multiple Myeloma.

Jia H, Zhang X, Liu X, Qiao R, Liu Y, Lv S Front Med (Lausanne). 2021; 8:667525.

PMID: 34249967 PMC: 8266212. DOI: 10.3389/fmed.2021.667525.

References

Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64. DOI: 10.1093/biostatistics/4.2.249. View

Gautier L, Cope L, Bolstad B, Irizarry R . affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3):307-15. DOI: 10.1093/bioinformatics/btg405. View

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

Zhang B, Horvath S . A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2006; 4:Article17. DOI: 10.2202/1544-6115.1128. View

Yip A, Horvath S . Gene network interconnectedness and the generalized topological overlap measure. BMC Bioinformatics. 2007; 8:22. PMC: 1797055. DOI: 10.1186/1471-2105-8-22. View

Chng W, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K . Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007; 67(7):2982-9. DOI: 10.1158/0008-5472.CAN-06-4046. View

Dong J, Horvath S . Understanding network concepts in modules. BMC Syst Biol. 2007; 1:24. PMC: 3238286. DOI: 10.1186/1752-0509-1-24. View

Rajkumar S, Buadi F . Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol. 2007; 20(4):665-80. DOI: 10.1016/j.beha.2007.10.002. View

Ruminy P, Jardin F, Picquenot J, Parmentier F, Contentin N, Buchonnet G . S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor cells. Blood. 2008; 112(5):1951-9. DOI: 10.1182/blood-2007-11-124560. View

10.

Langfelder P, Horvath S . WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008; 9:559. PMC: 2631488. DOI: 10.1186/1471-2105-9-559. View

11.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

12.

Kyrtsonis M, Maltezas D, Tzenou T, Koulieris E, Bradwell A . Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol. 2009; 46(2):110-7. DOI: 10.1053/j.seminhematol.2009.02.004. View

13.

Li A, Horvath S . Network module detection: Affinity search technique with the multi-node topological overlap measure. BMC Res Notes. 2009; 2:142. PMC: 2727520. DOI: 10.1186/1756-0500-2-142. View

14.

Tiedemann R, Zhu Y, Schmidt J, Yin H, Shi C, Que Q . Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2009; 115(8):1594-604. PMC: 2830764. DOI: 10.1182/blood-2009-09-243980. View

15.

Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A . Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010; 116(14):2543-53. DOI: 10.1182/blood-2009-12-261032. View

16.

Shi L, Campbell G, Jones W, Campagne F, Wen Z, Walker S . The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010; 28(8):827-38. PMC: 3315840. DOI: 10.1038/nbt.1665. View

17.

Carvalho B, Irizarry R . A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010; 26(19):2363-7. PMC: 2944196. DOI: 10.1093/bioinformatics/btq431. View

18.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

19.

Gozzetti A, Papini G, Defina M, Bocchia M . Extramedullary myeloma relapses. Ann Hematol. 2012; 91(9):1511-2. DOI: 10.1007/s00277-012-1432-3. View

20.

Oldham M, Langfelder P, Horvath S . Network methods for describing sample relationships in genomic datasets: application to Huntington's disease. BMC Syst Biol. 2012; 6:63. PMC: 3441531. DOI: 10.1186/1752-0509-6-63. View